Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 16 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Sulphonamide resistance in E. coli remains high, despite prescribing restriction

A substantial decrease in prescribing sulphonamides in the UK over the past decade has failed to reduce resistance to this class of antibiotics, conclude authors of a study in this week's issue of the Lancet.

News image

fiogf49gjkf04

There is a clear link between heavy antimicrobial use and the emergence of resistant bacteria. Whether a reduction in antimicrobial use can reverse this process is less certain.

Lucinda Hall, and David Livermore, and colleagues from St Bartholomew's and The Royal London School of Medicine and Dentistry, and the Central Public Health Laboratory, England, investigated the effect of the 1995 national restriction of sulphonamide prescribing in the UK on the prevalence of sulphonamide resistance in Escherichia coli.

Over 350 clinical isolates of E. coli were collected in 1991 and 1999, and the presence and locations of sulphonamide-resistance genes were assessed.

Frequency of E. coli sulphonamide resistance:
1991: 40%
1999: 46%
Lancet

Despite a huge decrease in sulphonamide prescriptions - from 3,208,000 prescriptions in 1991 to 77,000 in 1999 - the frequency of resistance remained high (165/359 [46%] in 1999 compared with 143/360 [40%] in 1991).

The prevalence of one specific resistance gene (SUL II) increased from 27% in 1991 to 36.5% in 1999.

Lucinda Hall comments, "We would like to think that if we stop using an antibiotic so much, resistance will go away, and we'll be able to use it again.

"Our study shows that we can't depend on this happening - once resistance to an antibiotic is common, it is going to be very difficult to get rid of. In part, this is because the genes that cause resistance to disused drugs, like sulphonamides, are linked to those that cause resistance to antibiotics we continue to use."

David Livermore adds, "Nevertheless, using antibiotics more carefully should slow the development of new resistance; and this - coupled with the development of new drugs - is vital if we are to keep ahead of the bacteria".

In an accompanying Commentary, Burke Cunha from Winthrop-University Hospital, Mineola, New York, USA, comments that the antibiotic resistance observed in Hall and colleagues' study is unsurprising. This is because the sulphonamide-restriction programme did not restrict the use of other antibiotics with high resistance potential commonly used in general practice, such as tetracycline and ampicillin.

Lancet 2001; 357 (9265): 1307, 1325
27 April 2001

Go to top of page Email this page Email this page to a colleague

 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 16 January 2018 
Bundle of care in GI cancer surgery
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 15 January 2018 
Risks of death after liver transplants for liver cancer
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Colonoscopy after colorectal cancer resection
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
PPI and Alzheimer's disease
 21 December 2017 
Health management for IBD
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 20 December 2017 
Management of abnormal liver blood tests
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 13 December 2017 
Disease severity in NAFLD
 13 December 2017 
Tryptophan metabolism and IBD activity
 12 December 2017 
Risk factors in undiagnosed cirrhosis
 12 December 2017 
Monitored anesthesia care for outpatient GI endoscopy
 12 December 2017 
High-risk colorectal cancer patients
 06 December 2017 
Reflux-induced chronic cough 
 06 December 2017 
Systemic inflammatory response syndrome in acute-on-chronic liver failure
 06 December 2017 
Preventing hepatic encephalopathy-related readmissions
 05 December 2017 
Thiopurines and colorectal cancer in IBD
 05 December 2017 
Childhood obesity into adulthood

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us